Levi & Korsinsky, LLP filed a securities‑fraud class action on Oct 31, 2025, against Baxter International Inc. The lawsuit alleges the company misled investors about the safety and performance of its Novum IQ Large Volume Pump (Novum LVP). The class period covers investors who purchased shares between Feb 23, 2022 and July 30, 2025.
The complaint claims Baxter concealed systemic defects in the Novum LVP that caused underinfusion, overinfusion, and non‑delivery of fluids, exposing patients to serious injury or death. It also alleges the company failed to issue adequate customer alerts and that statements about the pump’s safety, efficacy, and sales prospects were materially false and misleading.
The lawsuit seeks to recover losses for affected investors and sets a deadline of Dec 15, 2025 for investors to file as lead plaintiffs. The filing follows Baxter’s voluntary pause of Novum LVP shipments that began on July 31, 2025, a move that has weighed on the company’s financial performance.
Baxter reported its Q3 2025 results on Oct 30, 2025, with sales from continuing operations of $2.84 billion, a 5 % year‑over‑year increase, and adjusted diluted earnings per share of $0.69, exceeding analyst expectations of $0.60 but missing revenue forecasts of $2.88 billion. The Medical Products & Therapies segment saw a 1 % decline, partly due to lower infusion pump sales. The company also announced a leadership change, with Andrew Hider taking the role of President and CEO.
The FDA has classified the Novum LVP issues as a Class I recall, the most serious designation, and has issued warning letters to customers. Baxter has issued urgent medical device correction notices and warning letters to customers starting in April 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.